Pyridorin in Diabetic Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 328 participants.
Also called NCT02156843
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 328 participants
- Sponsor
- Registry
-
NCT02156843 -
2014-001641-24
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Bulgaria, France, Germany, Hong Kong SAR China, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain
- Registry status
- Terminated
Technical summary
Registry record NCT02156843. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pyridorin in Diabetic Nephropathy
- Acronym
- PIONEER
- Condition
- Diabetic Nephropathy
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- Pyridorin
- Intervention (Drug)
- Placebo
- Lead sponsor
- NephroGenex, Inc.
- Collaborator
- Collaborative Study Group (CSG)
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct02156843- Content hash
ec33d10985f583d914b3d71e4f770c17dd4718ad6d7951720c1b2eb5db3cadf3